Positive Press Coverage Somewhat Unlikely to Affect Loxo Oncology (LOXO) Share Price
Media headlines about Loxo Oncology (NASDAQ:LOXO) have been trending positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Loxo Oncology earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.3434640390946 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Loxo Oncology Inc (LOXO) Expected to Announce Earnings of -$1.27 Per Share (americanbankingnews.com)
- Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018 (prnewswire.com)
- ORYZON Appoints Clinical Development Leader Lori A. Kunkel, M.D., as a Scientific Advisor (marketwired.com)
- Loxo Oncology Inc (LOXO) Given Average Recommendation of “Buy” by Analysts (americanbankingnews.com)
Loxo Oncology (NASDAQ:LOXO) opened at $92.23 on Friday. Loxo Oncology has a 52-week low of $40.01 and a 52-week high of $106.40. The firm has a market capitalization of $2,717.13, a price-to-earnings ratio of -15.82 and a beta of 2.57.
In other news, Director Orbimed Advisors Llc sold 270,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $74.26, for a total value of $20,050,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Aisling Capital Iii Lp sold 500,000 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $75.00, for a total value of $37,500,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,628,396 shares of company stock valued at $125,989,430. Company insiders own 44.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Positive Press Coverage Somewhat Unlikely to Affect Loxo Oncology (LOXO) Share Price” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/positive-press-coverage-somewhat-unlikely-to-affect-loxo-oncology-loxo-share-price/1857322.html.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.